{
    "nct_id": "NCT06109779",
    "official_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)",
    "inclusion_criteria": "* Histologically confirmed adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma (CCA) or muscle invasive gallbladder cancer (GBC)) after macroscopically complete resection (R0 or R1)\n* Provision of a tumor sample collected at surgical resection.\n* Randomization within 12 weeks after resection with adequate healing and removal of drains.\n* Confirmed to be disease-free by imaging within 28 days prior to randomization.\n* Eastern Cooperative Oncology Group performance status of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants with locally-advanced, unresectable, or metastatic disease at initial diagnosis.\n* Ampullary cancer, neuroendocrine, mixed neuroendocrine and non-neuroendocrine neoplasms and nonepithelial tumors.\n* Any anti-cancer therapy for BTC prior to surgery\n* Active or prior documented autoimmune or inflammatory disorders or any severe or uncontrolled systemic disease\n* Current or prior use of immunosuppressive medication within 14 days before the first dose\n* Thromboembolic event within 3 months\n* Active HBV or HCV infection unless treated.",
    "miscellaneous_criteria": ""
}